A Paradigm Shift in Ocular Drug Delivery to Posterior Segment: Review on Current Drug Delivery Approaches

Ravi Kumar Koduru¹, Jigeesha Kasaraneni¹ and Ravi Kumar Reddy Juturi¹

¹Department of Pharmaceutics, Shri Vishnu College of Pharmacy (Autonomous), Bhimavaram -534202, Andhra Pradesh, India.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i40A32226

Editor(s):
(1) Dr. Mohamed Fawzy Ramadan Hassanien, Zagazig University, Egypt.

Reviewers:
(1) Samer Imad Mohammed, University of Baghdad, Iraq.
(2) Mona Abdel Mohsen, National Research Centre, Egypt.

Complete Peer review History: https://www.sdiarticle4.com/review-history/72133

Received 25 May 2021
Accepted 31 July 2021
Published 05 August 2021

ABSTRACT

Objectives: Owing to the increasing number of patients suffering from posterior eye disorders, efficient medicine delivery to the posterior segment is now in great demand in the clinical services. With unmet medical requirements, the posterior eye segment is an important therapeutic target. So, physicians should be informed of new indications and current strategies of drug delivery when new technologies enter the market.

Summary: The most common causes of vision impairment in developed nations are abnormalities of the posterior eye tissues. Poor drug distribution to lesions in patient's eyes is a key barrier to ocular disease therapy. The existence of barriers, such as the corneal barrier, aqueous barrier, and inner and outer blood-retinal barriers, severely limits medication accessibility in these locations. Because of its anatomical peculiarities, the posterior portion is particularly difficult to access for medications. The use of several new strategies for drug delivery is therefore a viable option for enhanced therapy of ocular disorders since recent advances in ocular drug delivery systems research have brought fresh insights into drug development.

Conclusion: This article provides an overview of several aspects of ocular medication
administration to the posterior region, with a focus on nano carrier-based approaches, suprachoroidal drug delivery system and ophthalmic devices, including the structure of the eye, its barriers, delivery routes, and the present status of drugs/devices.

Keywords: Ocular delivery; nanoparticles; posterior segment; retinal barriers.

1. INTRODUCTION

Pharmaceutical scientists are faced with one of the most appealing and hard endeavours: ophthalmic medication delivery. The eye is a multi-compartmental, tiny organ. Its anatomy, physiology, and biochemistry made it highly impervious to xenobiotics [1].

Of the total ocular diseases, 55% are posterior segment diseases, while these diseases may lead to permanent vision loss if left untreated. The number of diseases affecting the posterior eye segment is expanding at an alarming rate [2]. In industrialized countries, posterior segment ocular disorders are the most common cause of vision impairment. These diseases include, for example, age-related macular degeneration and diabetic retinopathy [3].

Over the last few decades, significant progress has been made in research, particularly in the development of advanced drug delivery systems aimed at delivering ocular therapeutics to target sites in an optimized and controlled manner, either by increasing penetration across mucosa or by extending the contact time of the carrier with the ocular surface. Emerging new controlled drug delivery systems such as dendrimers, microemulsions, mucoadhesive polymers, hydrogels, iontophoretic drug delivery, laser therapy along with sclera plugs, non-viral gene therapy, stem cells technology, and s-RNA based approaches are also developed. Advancement in material sciences and formulations has provided new exciting possibilities to deliver drugs to the posterior segment of the eye as well [1].

This review will give an update on recent case reports and updates on the recent progress and trends in ocular drug delivery systems.

1.1 The Anatomy and Physiology

The human eye is a globular structural organ that is around 24 mm in diameter. It generates a 3D mobile image that is frequently colored in natural light. The retina’s cone cells and rod cells aid in light detection and visual perception. Colors can be distinguished and depth perception can be discerned. It is divided into two sections: the anterior and posterior regions [4]. The eyeball is made up of three translucent layers: the outer coat, the tunica media, and the intima. The sclera is a tough tissue that runs from the back of the eye to the front, producing the cornea, which is transparent. The uveal coat in the middle is primarily made up of cribiform tissue that is densely vascularized and pigmented, and it is separated into three sections: the iris in front, the choroid in the back, and the ciliary body in between. The visual receptor is hidden behind the retina, which is a highly specialized neuronal membrane. In front of the ciliary body, it atrophies [5].

The cornea, which is roughly 0.5 mm thick and 11.5 mm in diameter, is connected to the larger posterior part, which includes the retina, vitreous humor, choroid, and the outermost white shell known as the sclera, by a distinct curve. With a diameter of around 24 mm, the posterior component makes up the remaining five-sixths [6]. The limbus is a connective tissue that connects the sclera and cornea. The iris is the pigmented framework around the eye center and the darkly colored pupil. The iris dilator and muscles in the sphincter govern the size of the pupil, which controls the amount of light that enters the eyes [1].

1.2 Ocular Pharmacokinetics: Barriers in Drug Delivery

Drugs can be administered locally or systemically to reach the ocular tissues. Drugs can’t get to their targets because of tissue barriers (Fig. 1). The ocular surface is protected by corneal and conjunctival epithelial barriers. The blood-aqueous barrier, which is made up of uveal capillary endothelia and ciliary epithelia, prevents chemicals from entering the anterior chamber from the systemic circulation, whereas the blood-retina barrier prevents drug diffusion from the systemic blood into the retina and vice versa. The outer and inner blood-retina barriers, created by the retinal pigment epithelium (RPE) and the
cornea. This has a detrimental impact to drug molecules, lowering the effective routes, resulting in drug loss at the targeted spot pathway may be absorbed by non-lipophilic medicines is the hydrophilic corneal diffusing through the paracellular pathway. The Tight junctions act as a selective barrier for tiny molecules, preventing macromolecules from diffusing through the paracellular pathway. The rate-limiting barrier for ocular absorption of most lipophilic medicines is the hydrophilic corneal stroma. Topically administered ocular medications that are not absorbed by the corneal pathway may be absorbed by non-corneal routes, resulting in drug loss at the targeted spot [1].

Tears consist of proteins and mucins that attach to drug molecules, lowering the effective concentration of medication in contact with the cornea. This has a detrimental impact on drug bioavailability.

![Fig. 1. Structure of eye](image)

(1) Trans-corneal permeation from the lachrymal fluid into the anterior chamber, (2) noncorneal permeation across conjunctiva and sclera into anterior uvea, (3) distribution of drug from the bloodstream through the blood-aqueous barrier into the anterior chamber, (4) drug elimination from the anterior chamber by aqueous humor passage into the trabecular meshwork and canal of Schlemm, (5) elimination of the drug from aqueous humor into the systemic circulation across the blood-aqueous barrier, (6) distribution of drug from blood into posterior eye across the blood-retina barrier, (7) intravitreal drug administration, (8) elimination of drug from vitreous through the posterior route across the blood-retina barrier, and (9) drug from vitreous through anterior route to the posterior chamber.

The blood-aqueous and blood-retina barriers are the two primary barriers in the intraocular environment. These two components prevent molecules from penetrating the eye chamber, resulting in ineffective intraocular tissue treatment [6].

The blood-ocular barrier (BOB) has three major purposes: it keeps infections out of the eye, regulates tissue/fluid composition, and creates aqueous humor. The blood-aqueous barrier is formed by tight junctions at the level of the iris vascular epithelium and non-pigmented ciliary epithelium, while the blood-retinal barrier is formed by tight junctions at the retinal pigment epithelium (RPE) and vascular endothelium levels [7] The BOB not only prevents germs from entering the eye but also prevents medications from entering. Surgery, uveitis, diabetes, and ocular infection, as well as specific therapies like photocoagulation and cryopexy, can all compromise this barrier. When the BOB fails, medicines can more readily enter and exit the eye; Starling forces (forces that govern fluid balance) can change, producing macular edema; and serum can leak into the eye, causing cellular proliferation and aqueous hyposecretion [8].
1.3 Route of Administration

Table 1. Advantages of various ocular routes of drug administration for posterior segment related diseases

<table>
<thead>
<tr>
<th>Route of administration</th>
<th>Advantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topical</td>
<td>Non-invasive, patient compliant</td>
</tr>
<tr>
<td>Systemic/intravenous</td>
<td>Less frequency of administration</td>
</tr>
<tr>
<td>Oral</td>
<td>Non-invasive, patient compliant</td>
</tr>
<tr>
<td>IVT</td>
<td>Less frequent dosing, depot action, and a direct local and long-lasting pharmacologic impact</td>
</tr>
<tr>
<td>Trans-scleral</td>
<td>Less invasive, easier to reach, vast surface area, suitability and comparatively greater permeability for both small and big compounds, depot action, large dosage administration, less adverse effects than IVT, no obstruction in the optic path</td>
</tr>
<tr>
<td>Suprachoroidal</td>
<td>Less invasive, depot action, direct impact on the choroid and outer RPE, favourable for small molecules, low systemic level of medication, lesser risk of adverse effects than IVT, no obstruction in the optic route</td>
</tr>
</tbody>
</table>

1.4 Strategies for Delivering Drugs to the Posterior Segment

There are three techniques of delivering medications to the eye from a conceptual standpoint:

1. Distribute vast amounts of medicines throughout the body

Drugs are usually given systemically in doses that are theoretically large enough to reach therapeutic levels in the eye. In reality, however, the BOB limits the number of medications that reach the posterior segment, necessitating systemic administration of extremely large dosages to obtain even borderline therapeutic retinal drug levels. The systemic toxicity related to the relatively high systemic medication levels required to overcome the BOB is typically a limiting issue in this strategy.

2. Introduce modifications to the BOB

Modifying the permeability of the BOB to allow better drug penetrance and access to specific medications and substances [e.g., histamines, bradykinin agonists, and vascular endothelial growth factor (VEGF)] that can enhance vascular permeability is the second route to drug administration. This method is rarely employed.

3. Drugs are delivered locally to the eye

The third technique entails delivering medications to the target tissues on a local level. There is evidence that local medication delivery to the posterior segment is the most successful technique for treating posterior segment disorders, and this is the strategy that is most usually employed in clinical practice [8].

2 CURRENT STATUS

Ocular drug delivery devices designed to maintain drug release are now available on the market or in clinical studies. The majority of them are used to treat long-term disorders of the eye's posterior portion. Macular degeneration, viral infections (such as CMV infections), glaucoma, ocular inflammations, dry eye syndrome, and retinal degenerations are all key indications for ocular drug delivery systems. The goal is to create a system that has increased ocular medication absorption and activity duration while posing a low risk of ocular problems.

2.1 Ocular Drug Delivery to Date

2.1.1 Implants

Implants are effective drug delivery systems for chronic ocular diseases. Implants once adjusted, in the eye, prolonged the drug residence time to an appropriate time. They are commonly used for the treatment of ocular disorders such as cytomegalovirus (CMV) retinitis which is an ocular infection occurs in AIDS patient and one of the leading to blindness. Earlier, non-biodegradable polymers were used but they needed surgical procedures for insertion and removal but now the trend has been changed to biodegradable ones. Biodegradable polymers such as PLA are safe and effective to deliver...
drugs in the vitreous cavity and show no toxic signs when inserted [7].

The implants have the advantages of (1) bypassing the blood–ocular barriers to delivering constant therapeutic levels of drug directly to the site of action, (2) avoiding the side effects associated with frequent systemic and intravitreal injections, and (3) requiring a smaller amount of drug during treatment [9]. The implants are always implanted intravitreally, in the pars plana of the eye (posterior to the lens and anterior to the retina), for intraocular delivery, which necessitates minimal surgery, some of the FDA approved implants are mentioned in Table 2 [3].

2.1.2 Microspheres

The medicament will be encapsulated in microparticles (1–1000 nm) or nanoparticles (1–1000 nm) using this carrier technology. Polymers that are biodegradable and biocompatible, such as polylactide and PLGA, which have both been approved by the FDA, are employed. These methods are primarily implanted through intravitreal injection, which is a less invasive method than surgery. They provide drugs for weeks or even months at a time, reducing the number of injections required [2]. Intravitreal injections of particle systems have the potential to produce vitreal clouding. Microparticles, on the other hand, tend to settle to the bottom of the vitreal cavity, but nanoparticles are more likely to induce clouding in the vitreous. It has been documented how erodible, non-erodible, and lipid microspheres can be used for ocular administration. In the polymer matrix, the drug is uniformly spread (monolithic system). As a result, the drug-loaded microparticles are suspended in a liquid carrier medium, which may also include the drug [10].

Sridhar Duvvuri et al., (2007) observed an ideal in vitro release of encapsulated ganciclovir was obtained by physically mixing microspheres prepared from different polymer blends before its dispersion in the thermo-gelling polymer. The formulation maintained mean vitreal concentrations of ganciclovir at approximately 0.8 micron/mL for 14 days, whereas direct injections could maintain drug levels above 0.8 microns/mL for 54 hours only [11].

Rocío Herrero-Vanrell et al. (2014) microspheres prepared from PLA and PLGA biomaterials are well tolerated after periocular and intravitreal injections in animals and humans. PLA and PLGA microspheres aggregate after injection, acting as an implant. Biodegradable microspheres might be useful in retinal healing in regenerative medicine [12].

Javier Rodríguez Villanueva et al., (2016) described an efficient and reproducible method for encapsulating Dexamethasone in biodegradable PLGA (50:50) microspheres [13].

Table 2. Implants approved for posterior segment disorder treatment

<table>
<thead>
<tr>
<th>Implants</th>
<th>current status</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitrasert</td>
<td>FDA approved in 1996</td>
<td>Ganciclovir-containing non-biodegradable polymer implant for the treatment of cytomegalovirus (CMV) retinitis. The drug is released for up to eight months.</td>
</tr>
<tr>
<td>Retisert</td>
<td>FDA approved in 2005</td>
<td>For the treatment of chronic non-infectious posterior uveitis, a non-biodegradable polymer implant containing fluocinolone acetonide is used. Fluocinolone is released for up to 2.5 years.</td>
</tr>
<tr>
<td>Ozurdex (formerly Posurdex®)</td>
<td>FDA approved in 2009</td>
<td>For the treatment of macular edema, the first biodegradable polymer implant containing dexamethasone was developed. A 22-gauge needle is inserted into the vitreous to release the medication for up to six months.</td>
</tr>
<tr>
<td>Iluvien (formerly Medidur®)</td>
<td>FDA approved in 2014</td>
<td>For the treatment of diabetic macular edema, a non-biodegradable implant containing fluocinolone acetonide is used. A 25-gauge needle is inserted into the vitreous to release the medication for up to three years.</td>
</tr>
<tr>
<td>Yutiq</td>
<td>FDA approved in 2018</td>
<td>It is a corticosteroid intravitreal implant indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.</td>
</tr>
</tbody>
</table>
2.1.3 Nano-particulates for drug delivery

2.1.3.1 Lipid nanoparticles

Three types of lipid nanoparticles, solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and hybrid lipid nanoparticles are often used in the studies. The former two nanoparticle systems typically form a solid lipid core and have the capability of loading both lipophilic drugs and hydrophilic drugs into the lipid matrix. SLN is strictly made up of more than one solid lipids, whose melting point is above 40°C. SLN shows the advantages of controlled release dating from the early 1990s [14], reduced toxicity for cells, high compatibility, and in vivo tolerability [15]. NLC containing liquid lipids and solid lipids in their components appear with the advantages of higher drug-loading capacity, better stability during storage, and improved release properties compared to SLN. Nevertheless, hybrid lipid nanoparticles modified by multifunctional polymers [16], combine the merits of polymeric nanoparticles and lipid-based systems, which simultaneously improve pharmacokinetics and biodistribution of the loaded drug.

Patrizia Chetoni et al. (2016) discovered that following ocular and intravenous administration of Tobra-SLN formulations, drug concentrations were considerably greater in all ocular tissues compared to reference formulations, and only Tobra-SLN permitted drug penetration into the retina. The current work adds to our understanding of the utilization of SLN as carriers for ocular medication transport to the posterior chamber and might lead to novel treatment options for ocular infections, as well as a strategy to combat microbial resistance [17].

Balguri et al., (2017) successfully prepared indomethacin (IN)-loaded lipid nanoparticles (IN-SLN, IN-CS (chitosan chloride)-SLN and IN-NLC) by a hot homogenization method. Then the disposition of IN from these topically administered formulations to the posterior eye was evaluated [18].

Joana Araújo et al., (2011) study is about Triamcinolone acetonide (TA) which is a corticosteroid drug currently administered by intravitreal injection for a broad spectrum of inflammatory, edematous, and angiogenic ocular diseases. To increase the drug’s bioavailability by ocular instillation, TA was encapsulated in nanostructured lipid carriers (NLC), previously optimized by their group using a factorial design approach [19].

2.1.3.2 Nanoparticles

Polymeric nanoparticles of colloidal nanosized systems (1 nm<d<1000nm) are ideally appropriate for ocular medication administration to the required locations due to the variety of polymers in their compositions [20]. Because of their structural differences, polymeric nanoparticles are divided into nanospheres and nano-capsules. Nanospheres have a polymeric matrix with three drug-loading options: (1) encapsulating medicines in the spheres, (2) absorbing drugs on the surface, and (3) dispersing medications throughout the polymeric network. In contrast, the drug-loading forms of core-shell nano-capsules are restricted to dissolve drugs in the core or absorb medications on the shell [21]. The polymers utilized in the nanoparticles are natural materials or modified ones, such as natural materials chitosan, dextran sulfate, hyaluronic acid, and synthetic polymers poly (lactic acid) (PLA), poly(lactic-co-glycolic-acid) (PLGA), poly(ε-caprolactone). The polymeric nanoparticles can enhance the pre-cornea retention period and are biocompatible and biodegradable for ocular application. Furthermore, to employ polymers in ocular medication administration, it is critical to assess their potential toxicity [22].

Wai-Leung Langston Suen et al., (2013) presented folate-decorated polymeric nanoparticles as carriers for poorly soluble therapeutic compounds to be delivered intracellularly and for a long time to RPE cells. Internalization of these nanoparticles into ARPE-19 (human RPE cell line) via receptor-mediated endocytosis resulted in considerably greater cellular absorption than particles without folate treatment. Triamcinolone acetonide (TA) was successfully encapsulated (>97%) within the folate-decorated nanoparticles and slowly released over 4 weeks at pH 5.5 and 8 weeks at pH 7.4 [23].
polycaprolactone-polylactic acid (PLA-PCL-PEG-PCL-PLA) for sustained protein delivery [24].

Naba Elsaid et al. (2016) analysed the effects of incorporating chitosan-based nanoparticles containing ranibizumab within the PLGA microparticles on the loading, stability, activity, and release of the ranibizumab, as well as their effects on the physicochemical properties of the PLGA microparticles [25].

2.1.3.3 Liposomes

Liposomes are self-assembled vesicles and form when lipid materials are dispersed in an aqueous medium. The nanosized liposomes are made up of phospholipid bilayers with aqueous units that can transport both hydrophilic and hydrophobic medicinal molecules to the target locations [22]. The biocompatible phospholipids used to formulate liposomes mainly include phosphatidylserine (PS), soya phosphatidylcholine, phosphatidylcholine (PC), and phosphatidylethanolamine, which are similar to the lipid on the cell membrane and could enhance pre-corneal permeation [26].

The very next generation liposome, which has been engineered with mucoadhesive and penetration-enhancing polymers, may not only entrap drug molecules but also target specific locations on the cornea by adhering to the surface [27].

Hirofumi et al. (2012) prepared diclofenac-loaded multilamellar liposomes that are modified by polyvinyl alcohol (PVA 205) and polyvinyl alcohol derivatives (PVA-R) through the calcium acetate gradient method for the first time [28].

T Lajunen et al. (2014) developed methods of liposome preparation utilizing a microfluidizer to achieve adjustable nanoparticle size (even less than 80 nm) and high loading capacity of plasmid DNA [29].

K Pachis et al. (2017) effectively introduced a new Flurbiprofen (FLB)-in-liposome-in-hydrogel formulation as a strategy to prolong FLB release and boost ocular bioavailability after intravitreal injection. FLB loading into liposomes was improved for this, and liposomes were entrapped in Pluronic F-127 thermosensitive hydrogels (P) [30].

2.1.3.4 Nano micelles

Nano micelles are colloidal drug delivery devices that may entrap therapeutic chemicals at their core and self-assemble in a solution. They are formed up of amphiphilic surfactants or block copolymers and range in size from 10 to 200 nm. When the concentration of polymers in a solution exceeds a certain concentration known as the critical micellar concentration (CMC), nano micelles form instantly. Because of hydrophobic interactions, nano micelles can encapsulate hydrophobic medicines in the hydrophobic core of the micelles. While the hydrophilic corona interacts with the external aqueous fluid, a somewhat lipophilic drug's solubility is increased. This colloidal dosage form may be used to make clear aqueous solutions that may be used as eye drops. Surfactant nano micelles and polymeric nano micelles are two types of nano micelles [31].

TRavi D. Vaishya et al. (2014) created polymeric nano micelles encapsulated with dexamethasone (DEX). Ex vivo permeability and stiff nano micelle core results suggest that these nano micelles might carry DEX and other hydrophobic anti-inflammatory drugs like rapamycin to the back of the eye via a topical route for the treatment of intermediate to posterior segment uveitis [32].

2.1.4 Iontophoresis

Many medicines, including fluorescein, hormones, antibiotics, antivirals, and macromolecules, have been demonstrated to promote transscleral permeability using iontophoresis. It is a non-invasive approach that uses a tiny electric current to increase the penetration of an ionized medication into the tissue [5]. With negligible side effects, transscleral iontophoresis delivers large concentrations of the administered medicine to the choroid and retina. Epithelial edema, a reduction in endothelial cells, inflammatory infiltration, and burns are all side effects of iontophoresis, the severity of which varies depending on the place of application, current density, and duration. Iontophoresis has been proven to harm the choroid and destroy retinal layers at greater current densities [7].

S Pescina et al. (2013) investigated in vitro transscleral iontophoresis of methylprednisolone hemisuccinate using concentrated drug solutions and short application times to mimic the iontophoretic conditions of in vivo studies [33].

Verena Santer et al. (2018) investigated short duration transscleral iontophoretic delivery of four triamcinolone acetonide (TA) amino acid ester prodrugs (TA-AA) (alanine, Ala; arginine, Arg;
isoleucine, Ile and lysine, Lys) using whole porcine eyes globes in vitro. When compared to passive diffusion, transcleral iontophoresis (3 mA/cm² for 10 min) boosted the overall drug distribution of the TA-AA prodrugs by 14-30 times. The study added to the growing body of data that transcleral iontophoresis has the potential to treat posterior segment inflammatory disorders non-invasively [34].

3. CURRENT STRATEGIES

IVT injections and implants, as well as systemic intravenous injections, are now the most common methods of delivering medications to the posterior portion of the eye. Elevated VEGF, depleted antioxidants, and inflammation are reported to be key culprits in most posterior segment disorders such as DR, RVO, DME, AMD, CNV, CMV retinitis, and so on.

3.1 Intravitreal Injections of Anti-VEGF Agents

The earliest mention of VEGF in ophthalmology is from 1940 when a group of scientists claimed that a diffusible factor was responsible for proper vasculature development. In proliferative diabetic retinopathy, an imbalance in the particular factor resulted in neovascularization (DR). VEGF was discovered to be a possible mediator of choroidal and intraocular neovascularization in individuals with age-related macular degeneration in the late 1990s (AMD).

In numerous animal models, proof of concept studies showed that VEGF blockade inhibited neovascularization, indicating that VEGF blockade might be a possible new method to overcome retinal illnesses involving neovascularization [8].

Xiangke Yin et al. (2019) developed RFP (DAVP2 and DAVP3) showed suppression of endothelial cell migration and proliferation and, inhibition of angiogenesis in a laser-induced choroidal neovascularization mouse model after intravitreal injections by inhibiting not only VEGF but also platelet-derived growth factor through suppression of the phosphorylation activation processes in the metabolic cascade [35].

In a study conducted by Raquel Lima e Silva et al. (2017), a collagen IV-derived peptide called “AXT 107” was produced, which functioned by coupling to VEGF and platelet-derived growth factor receptors. In many in vivo studies, it suppressed subretinal and retinal neovascularization [36].

3.2 Suprachoroidal Drug Delivery Through Hollow Microneedles

The delivery of treatments in the suprachoroidal region has shown promise in terms of delivering therapeutic drugs at a higher concentration to the target tissue (retina and choroid). Anatomical investigations indicating the diffusion of therapeutic substances following drug application at the suprachoroidal space support this theory.

Patel et al., (2012) demonstrated suprachoroidal drug delivery through the posterior pars plana of a rabbit model using a hollow microneedle. The suprachoroidal drug delivery was a minimally invasive procedure demonstrating safe delivery into the retina and choroid with no adverse effects [37].

Jae Hwan Jung et al. (2019) investigated suprachoroidal space (SCS) injection formulation with collagenase to improve drug delivery coverage and boost posterior drug targeting inside SCS by breaking down collagen fibrils that connect the sclera and choroid in the SCS [38].

3.3 Ophthalmic Devices

Due to its efficacy in restoring normal visual acuity, ocular implants and medication delivery systems have attracted a lot of attention in recent years [9]. These devices can be non-biodegradable, biodegradable, or stimuli-responsive systems that are implanted into the eye for drug delivery or to repair a defect. Drug delivery systems have become more important in recent years as a result of their capacity to administer medicine or drug in a regulated and sustained way for both the anterior and posterior segments of the eye [39]. The following ophthalmic equipment which are given in Table 3 are extremely important in the diagnosis, treatment, and monitoring of posterior segment illnesses [40].

3.4 Nano-formulations

Nanotechnology has infiltrated every facet of medicine, and ocular therapies cannot be left behind. Liposomes, microspheres, dendrimers, and other nano-formulations have been used to treat illnesses of the posterior portion of the eye.
### Table 3. Recent ophthalmic devices in pipeline for posterior segment treatment

<table>
<thead>
<tr>
<th>Device</th>
<th>Status</th>
<th>Description</th>
<th>Benefits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yutiq</td>
<td>FDA approved in 2018</td>
<td>It’s an intravitreal micro insert that isn’t bio-erodible.</td>
<td>It offers convenience because it can be injected with a small-gauge needle.</td>
</tr>
<tr>
<td>GB-102</td>
<td>Phase 2 trails Other Name: Sunitinib malate</td>
<td>It encapsulates sunitinib malate within bioabsorbable microparticles</td>
<td>It allows us to provide a more sustainable treatment strategy.</td>
</tr>
<tr>
<td>AR-1105</td>
<td>Phase 2 trails</td>
<td>It is a bio-erodible implant that is injected intravitreally.</td>
<td>It offers 6 months duration of sustained efficacy, improved administration due to smaller needle size, and possibly a better safety profile due to lower peak drug levels.</td>
</tr>
</tbody>
</table>

### Table 4. Current potential nanotechnology strategies for treatment of posterior segment disorders

<table>
<thead>
<tr>
<th>Nano-formulations</th>
<th>Drug/ingredients</th>
<th>Output</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solid Lipid Nanoparticles</td>
<td>Lipid-polyethylene glycol matrix solid lipid nanoparticles Fluconazole</td>
<td>FCZ-SLN effectiveness was not harmed by encapsulation within SLNs or gradual release. The developed system was safe and stable (even after autoclaving), with ideal viscosity, refractive index, and osmotic pressure.</td>
<td>Shilpa Kakkar et al., (2021) [43]</td>
</tr>
<tr>
<td>Microsphere</td>
<td>Glial cell line-derived neurotrophic factor-GDNF and Tauroursodeoxycholic acid-TUDCA</td>
<td>The in vitro release of these optimized microparticles was sustained for 91 days. These findings indicate that the microencapsulation process used in this study is a potential technical technique for developing multi-loaded intraocular medication delivery devices (IODDS).</td>
<td>Alicia Arranz-Romera et al., [44]</td>
</tr>
<tr>
<td>Nano-Structured Lipid Carriers</td>
<td>Dexamethasone</td>
<td>At 34.4°C, NLCs-gel showed a quick sol-gel transition and nano-sized, narrowly scattered particles. NLCs-gel enhanced ocular bioavailability by lengthening preconeal retention time and enhancing corneal permeability, according to Ritger-Peppas corneal penetration trials.</td>
<td>Zhenjie Mo et al., [45]</td>
</tr>
<tr>
<td>Liposomes</td>
<td>Triamcinolone acetonide</td>
<td>When administered on the ocular surface, a topical ophthalmic TA-loaded liposomes formulation (TALF) was intended to transport TA into the posterior section of the eye.</td>
<td>Jose Navarro-Partida et al., [46]</td>
</tr>
</tbody>
</table>

114
Nanoformulations | Drug/ingredients | Output | Reference |
--- | --- | --- | --- |
 | | | eye. In either of the animal or clinical tests, no inflammation, lens opacity, edema, or rise in intraocular pressure was seen following the instillation of TALF. | |
 | Dorzolamide and Dexamethasone | γ-cyclodextrin (γ-CD)-based nanoparticle aggregates were used to create eye drop formulations. This technique has the potential to be utilized with various types of pharmacological molecules and to replace or augment invasive treatments, resulting in safer, non-invasive medicines that may be self-administered as eye drops by patients, particularly for posterior segment diseases. | Thorsteinn Loftsson et al., [47] |
 | | Resveratrol | The suggested formulation revealed potential cellular uptake and anti-angiogenic properties by reducing VEGF expression in vitro, according to cellular uptake and VEGF expression levels for the created nanoparticles. The findings demonstrated that resveratrol-loaded nanoparticles might be utilized alone or in combination with anti-VEGF agents to treat neovascular AMD. | Priyanka Bhatt et al., [48] |
 | Fluocinolone acetonide (FA) and PLGA nanoparticles | FA was released continuously from the NPs for 30 days in an in vitro drug release investigation. | Joyce Pinto et al., [49] |
 | Everolimus | When compared to everolimus suspension, the nano micelles were shown to have a high encapsulation efficiency and result in the prolonged release of everolimus. The penetration of everolimus nano micelles over goat cornea was substantially greater than that of everolimus suspension (p<0.001). | Nikita Mehra et al., [50] |

Enhanced penetration and retention, bypass of the reticuloendothelial system, fast internalization, and biocompatibility are just a few of the benefits they provide. For regulated and sustained drug administration via diverse channels, several bio-degradable, tunable polymers and lipids are being studied [42]. Many nano-formulations, such as nanostructured lipid carrier (NLC), liposome, NP, emulsion, are being tested preclinically for drug delivery to the posterior portion of the eye and are showing promising results [7]. These nano-formulations are currently being used to have a favorable influence on biological molecules (peptide, protein, gene, oligonucleotide, monoclonal antibody, etc.), starting with delivering synthetic chemical moieties to target tissue. Current potential nanotechnology strategies for treatment of posterior segment disorders are detailed in the Table 4.
4. CONCLUSION

Intricate structure and physiology of the eye, recommends local treatment for eye illness. Disorders associated with the anterior segment of the eye are usually treated with topical formulations such as eye drops, ointments, ocular inserts, etc. Whereas, chronic disorders affecting the posterior segment need specific treatment other than topical formulations, as they are ineffective in this case, thus enabling the need for a new DDS.

In this review article, we investigated new DDS with several strategies that showed potential enhancement in the treatment of posterior segment disorders. Nanotechnology-based formulations with improved penetration and retention for efficient long-term drug release have been reported. Ophthalmic devices offer convenience and sustained efficacy in restoring normal visual acuity. Intravitreal injections of Anti-VEGF Agents showed VEGF blockade to overcome retinal illnesses involving neovascularization whereas Suprachoroidal Drug Delivery through hollow microneedles boost posterior drug targeting inside SCS and showed promising delivery of therapeutic drugs at a higher concentration into the retina and choroid demonstrating safe delivery with no adverse effects.

Longer-acting medication administration and good long-term illness control are now possible thanks to technological advancements. Greater target specificity, potentially real-time monitoring of active drug levels, and reciprocal dosage changes will be possible with future devices.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

ACKNOWLEDGEMENT

I’m very thankful to Faculty at Department of Pharmaceutics and Pharmaceutical Regulatory Affairs Shri Vishnu College of Pharmacy (Autonomous), Bhimavaram- 534202. I would also like to thank the Management for providing the necessary facilities to carry out this work.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES


16. Das S, Ng WK, Tan RBH. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci. 2012;47(1). DOI: 10.1016/j.ejps.2012.05.010


DOI: 10.1016/j.ijpharm.2012.07.024

DOI: 10.1016/j.ejps.2014.04.018

DOI: 10.1016/j.ejps.2017.08.028

DOI: 10.1208/s12249-014-0100-4

DOI: 10.1208/s12249-014-0100-4

DOI: 10.1016/j.ejpb.2016.07.009

DOI: 10.1016/j.ejpb.2018.09.020

DOI: 10.1016/j.phrs.2019.104277

DOI: 10.1126/scitranslmed.aai8030

DOI: 10.1167/iovs.12-9872

DOI: 10.1016/j.exer.2019.107824

DOI: 10.1016/j.jddst.2019.04.038

40. Baker-Schena L. Drug delivery for the posterior segment the posterior segment. Eyenet Mag. 39-44.

DOI: 10.1016/j.sjopt.2014.02.009

DOI: 10.3390/jfb6020379

DOI: 10.1080/1061186X.2020.1871483

DOI: 10.1007/s13346-021-00930-9

DOI: 10.1016/j.msec.2020.111445


